Plaintiffs filing Tepezza hearing loss lawsuits claim Horizon Therapeutics, the manufacturer, knew for years that the thyroid eye disease was linked to widespread reports of hearing problems.
The FTC has agreed to allow Amgen to buy Horizon, the manufacturer of Tepezza, after proposing a consent decree which seeks to prevent the company from gaining an overwhelming advantage…
Plaintiffs and defendants in Tepezza litigation have filed dueling bellwether selection protocols which would lead to the first early test cases over claims the thyroid eye disease drug causes hearing…
A Tepezza hearing loss lawsuit claims a man suffered permanent hearing damage after receiving infusions of the thyroid eye disease drug.
Parties will meet on July 31 to discuss the next steps in moving Tepezza hearing loss litigation forward.
The FDA has added new Tepezza hearing loss label warnings, alerting patients and healthcare professionals to the risk of permanent hearing damage linked to the thyroid eye disease drug.
Nearly 17% of users report suffering hearing problems from Tepezza over the first six months of use, according to the findings of a new study.
A federal judge has appointed 12 Tepezza injury attorneys to leadership positions for the consolidated legislation over hearing damage linked to the thyroid eye disease drug.
A product liability lawsuit claims Horizon Therapeutics should have warned doctors to test patients' hearing before and after Tepezza infusions to help prevent permanent hearing damage.
The initial status conference for Tepezza hearing damage lawsuits consolidated before one judge for pretrial proceedings, is scheduled for June 28.
